M&A Deal Summary |
|
|---|---|
| Date | 2016-08-24 |
| Target | AstraZeneca - Small Molecule Anti-Infective Business |
| Sector | Life Science |
| Buyer(s) | Pfizer |
| Sellers(s) | AstraZeneca |
| Deal Type | Divestiture |
| Deal Value | 550M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 8,300 |
| Revenue | 58.5B USD (2023) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 30 of 43 |
| Sector (Life Science) | 26 of 39 |
| Type (Divestiture) | 5 of 5 |
| Country (United Kingdom) | 3 of 4 |
| Year (2016) | 5 of 5 |
| Size (of disclosed) | 16 of 21 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-08-22 |
Medivation
San Francisco, California, United States Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. |
Buy | $14.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-06 |
Pfizer - Hospira Infusion Systems Business
New York, United States Pfizer, Inc. - Hospira Infusion Systems Business includes IV pumps, solutions, and devices. |
Sell | $1.0B |
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 45.8B USD (2023) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 11 |
| Sector (Life Science) | 4 of 7 |
| Type (Divestiture) | 7 of 11 |
| Country (United Kingdom) | 2 of 5 |
| Year (2016) | 1 of 2 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-17 |
Acerta Pharma BV
Oss, Netherlands Acerta Pharma is a cancer drug developer with operations in the Netherlands and in California. |
Buy | $4.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-04 |
AstraZeneca - Toprol-XL
London, United Kingdom AstraZeneca Plc - Toprol-XL is a provider of treatment of high blood pressure. By lowering blood pressure, Toprol-XL may lower the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Toprol-XL is also indicated for the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance and for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. |
Sell | $175M |
